We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

155 hedge funds and large institutions have $1.32B invested in Karyopharm Therapeutics in 2020 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 65 increasing their positions, 33 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more call options, than puts

Call options by funds: $14.8M | Put options by funds: $6.38M

97% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 33

91% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 23

14% more funds holding

Funds holding: 136 → 155 (+19)

1% more capital invested

Capital invested by funds: $1.31B → $1.32B (+$13.4M)

0.04% more ownership

Funds ownership: 6.31% → 6.36% (+0.04%)

56% less funds holding in top 10

Funds holding in top 10: 9 → 4 (-5)

Holders
155
Holders Change
+19
Holders Change %
+13.97%
% of All Funds
3.18%
Holding in Top 10
4
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-55.56%
% of All Funds
0.08%
New
44
Increased
65
Reduced
33
Closed
23
Calls
$14.8M
Puts
$6.38M
Net Calls
+$8.46M
Net Calls Change
+$7.97M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$26.6M
2
BlackRock
BlackRock
New York
+$21M
3
Goldman Sachs
Goldman Sachs
New York
+$20.5M
4
FCM
Frontier Capital Management
Massachusetts
+$18.8M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$11.3M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$62.5M
2
Citadel Advisors
Citadel Advisors
Florida
-$27M
3
CCM
Consonance Capital Management
New York
-$13.6M
4
CS
Candriam SCA
Luxembourg
-$11.6M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$9.36M
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
26
Woodline Partners
California
$8.77M +$9.13M +30,882 New
Charles Schwab
27
Charles Schwab
California
$8.4M +$1.14M +3,838 +15%
GIM
28
Granahan Investment Management
Massachusetts
$8.3M +$8.64M +29,205 New
N
29
Nuveen
North Carolina
$8.01M +$2.73M +9,235 +49%
SFM
30
Sphera Funds Management
Israel
$7.44M -$3.1M -10,478 -29%
AI
31
Atom Investors
Texas
$7.38M -$1.62M -5,492 -17%
Macquarie Group
32
Macquarie Group
Australia
$7.22M +$26.3K +89 +0.4%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$6.06M -$146K -495 -2%
JP Morgan Chase
34
JP Morgan Chase
New York
$5.14M +$265K +897 +5%
CS
35
Candriam SCA
Luxembourg
$4.91M -$11.6M -39,060 -69%
Millennium Management
36
Millennium Management
New York
$4.5M +$4.69M +15,846 New
Two Sigma Investments
37
Two Sigma Investments
New York
$4.46M -$3.98M -13,459 -46%
CS
38
Credit Suisse
Switzerland
$4.44M +$2.84M +9,603 +160%
Deutsche Bank
39
Deutsche Bank
Germany
$4.38M +$1.58M +5,345 +53%
Balyasny Asset Management
40
Balyasny Asset Management
Illinois
$4.22M +$4.4M +14,870 New
Allianz Asset Management
41
Allianz Asset Management
Germany
$3.78M +$2.05M +6,945 +109%
Renaissance Technologies
42
Renaissance Technologies
New York
$3.44M -$6.94M -23,480 -66%
Wells Fargo
43
Wells Fargo
California
$3.42M +$2.31M +7,826 +185%
Morgan Stanley
44
Morgan Stanley
New York
$3.4M +$2.36M +7,989 +201%
BC
45
Birchview Capital
Vermont
$3.18M +$394K +1,333 +14%
MOACM
46
Mutual of America Capital Management
New York
$3.06M +$467K +1,578 +17%
California Public Employees Retirement System
47
California Public Employees Retirement System
California
$2.97M +$471K +1,592 +18%
Bank of America
48
Bank of America
North Carolina
$2.83M +$983K +3,325 +50%
QI
49
QS Investors
New York
$2.77M -$4.73K -16 -0.2%
PPA
50
Parametric Portfolio Associates
Washington
$2.74M -$270K -914 -9%
1
2
3 4 5

KPTI Hedge Fund Activity: Q2 2020 in Review

155 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2020, worth a combined $1.32B — up 1% from $1.31B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new KPTI positions and 23 closed out — a net gain of 21 holders — while 65 added to existing stakes and 33 trimmed.

The largest buyer was State Street, adding an estimated $26.6M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $62.5M sold.

  • 155 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2020, up from 136 in Q1 2020.
  • Funds reported $1.32B of Karyopharm Therapeutics stock for Q2 2020, up 1% quarter-over-quarter.
  • 44 funds opened new Karyopharm Therapeutics positions in Q2 2020 and 23 closed out, a net change of +21 holders.
  • The largest Karyopharm Therapeutics buyer in Q2 2020 was State Street, an estimated $26.6M added.
  • The largest Karyopharm Therapeutics seller in Q2 2020 was Janus Henderson Group, an estimated $62.5M sold.

Based on aggregated 13F filings for Q2 2020.